Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 12/2013

Open Access 01-12-2013 | Letter to the editor

Reply to Molassiotis

Authors: Edzard Ernst, Paul Posadzki

Published in: Supportive Care in Cancer | Issue 12/2013

Login to get access

Excerpt

Molassiotis is the author of about 40 reviews, all of which are prone to the shortcomings he highlights. His statement, “I urge researchers in the field not to proliferate publications of ‘systematic’ reviews of a very small number and of admittedly poor/low quality level trials”, is thus surprising to say the least. The main point of his response seems to be that “systematic reviews of few and low-quality studies do not help anybody”. We feel that such articles can still be useful, for instance, for disclosing important deficits in our current knowledge. …
Metadata
Title
Reply to Molassiotis
Authors
Edzard Ernst
Paul Posadzki
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1990-5

Other articles of this Issue 12/2013

Supportive Care in Cancer 12/2013 Go to the issue

Original Article

Changes of QTc interval after opioid switching to oral methadone

Original Article

Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspective

Original Article

Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems

Original Article

Orphan symptoms in advanced cancer patients followed at home

Letter to the editor

Author's response to ‘Evidence is in the eye of the beholder’ letter to the editor

Original Article

Cancer pain management in an oncological ward in a comprehensive cancer center with an established palliative care unit
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits